Trial · NCT01408901
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 6-Week Follow-Up | STARTED | A: GM-CSF + Supervised Treadmill Exercise Therapy | 53 | |
| 6-Week Follow-Up | STARTED | B: GM-CSF + Attention Control Group | 53 | |
| 6-Week Follow-Up | STARTED | C: Placebo + Supervised Exercise Therapy | 53 | |
| 6-Week Follow-Up | STARTED | D: Placebo + Attention Control Group | 51 | |
| 6-Week Follow-Up | COMPLETED | A: GM-CSF + Supervised Treadmill Exercise Therapy | 50 | |
| 6-Week Follow-Up | COMPLETED | B: GM-CSF + Attention Control Group | 51 | |
| 6-Week Follow-Up | COMPLETED | C: Placebo + Supervised Exercise Therapy | 50 | |
| 6-Week Follow-Up | COMPLETED | D: Placebo + Attention Control Group | 47 | |
| 6-Week Follow-Up | NOT COMPLETED | A: GM-CSF + Supervised Treadmill Exercise Therapy | 3 | |
| 6-Week Follow-Up | NOT COMPLETED | B: GM-CSF + Attention Control Group | 2 | |
| 6-Week Follow-Up | NOT COMPLETED | C: Placebo + Supervised Exercise Therapy | 3 | |
| 6-Week Follow-Up | NOT COMPLETED | D: Placebo + Attention Control Group | 4 | |
| 12-Week Follow-Up (Primary Endpoint) | STARTED | A: GM-CSF + Supervised Treadmill Exercise Therapy | 50 | |
| 12-Week Follow-Up (Primary Endpoint) | STARTED | B: GM-CSF + Attention Control Group | 52 | |
| 12-Week Follow-Up (Primary Endpoint) | STARTED | C: Placebo + Supervised Exercise Therapy | 50 | |
| 12-Week Follow-Up (Primary Endpoint) | STARTED | D: Placebo + Attention Control Group | 49 | |
| 12-Week Follow-Up (Primary Endpoint) | COMPLETED | A: GM-CSF + Supervised Treadmill Exercise Therapy | 49 | |
| 12-Week Follow-Up (Primary Endpoint) | COMPLETED | B: GM-CSF + Attention Control Group | 50 | |
| 12-Week Follow-Up (Primary Endpoint) | COMPLETED | C: Placebo + Supervised Exercise Therapy | 50 | |
| 12-Week Follow-Up (Primary Endpoint) | COMPLETED | D: Placebo + Attention Control Group | 46 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01408901/flow